A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome

被引：0
|
作者：
Komrokji, Rami S. [1 ]
Carraway, Hetty E. [2 ]
Germing, Ulrich [3 ]
Wermke, Martin [4 ]
Zeidan, Amer M. [5 ]
Fu, Eric [6 ]
Rueter, Bjoern [7 ]
Burkard, Ute [7 ]
Osswald, Annika [7 ]
Foran, James M. [8 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL 33612 USA
[2] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH USA
[3] Heinrich Heine Univ Dusseldorf, Univ Klinikum Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[4] Tech Univ, Med Fac Carl Gustav Carus, NCT UCC ECTU, Dresden, Germany
[5] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT USA
[6] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[7] Boehringer Ingelheim Pharm GmbH & Co KG, Biberach, Germany
[8] Mayo Clin, Dept Hematol & Med Oncol, Jacksonville, FL USA
来源：
HAEMATOLOGICA | 2022年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2742 / 2747
页数：6
相关论文
共 50 条
  • [21] A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis
    Johnson, M. L.
    Gort, E.
    Pant, S.
    Lolkema, M. P.
    Sebastian, M.
    Scheffler, M.
    Hwang, J.
    Duenzinger, U.
    Riemann, K.
    Kitzing, T.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S591 - S592
  • [22] Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload
    Ivars, David
    Teresa Orero, Maria
    Javier, Karla
    Diaz-Vico, Laura
    Luis Garcia-Gimenez, Jose
    Mena, Salvador
    Tormos, Carmen
    Egea, Mercedes
    Luis Perez, Pedro
    Arrizabalaga, Beatriz
    Angeles Ruiz, Maria
    Yague, Nuria
    Tormo, Mar
    Sancho-Tello, Reyes
    Gomes, Angela
    Alguero, Carmen
    Enrique O'Connor, Jose
    Saez, Guillermo T.
    Carbonell, Felix
    Collado, Rosa
    CLINICAL BIOCHEMISTRY, 2017, 50 (16-17) : 911 - 917
  • [23] Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial
    Gonzalez-Lugo, Jesus D.
    Kambhampati, Suman
    Yacoub, Abdulraheem
    Donnellan, William B.
    Berdeja, Jesus
    Bhagat, Prafulla
    Fehn, Karen
    Remy, Cassady
    Jasra, Sakshi
    Kazemi, Mohammed
    Pradhan, Kith
    Kim, Mimi
    Mantzaris, Ioannis
    Sica, R. Alejandro
    Shah, Nishi
    Goldfinger, Mendel
    Kornblum, Noah
    Gritsman, Kira
    Braunschweig, Ira
    Steidl, Ulrich
    Will, Britta
    Shastri, Aditi
    Verma, Amit
    CLINICAL CANCER RESEARCH, 2023, 29 (01) : 60 - 66
  • [24] Open-label, phase I/II dose-escalation study of ARANESP™ in patients with chronic anemia of cancer.
    Glaspy, J
    Meza, L
    Smith, R
    Fleishman, A
    Mendes, E
    Colowick, A
    BLOOD, 2000, 96 (11) : 154B - 155B
  • [25] Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure
    Jabbour, Elias J.
    Garcia-Manero, Guillermo
    Strati, Paolo
    Mishra, Asmita
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    Kadia, Tapan
    Daver, Naval
    O'Brien, Susan
    Steensma, David P.
    Sekeres, Mikkael A.
    Gore, Steven D.
    Dezern, Amy
    Roboz, Gail J.
    List, Alan F.
    Kantarjian, Hagop M.
    Komrokji, Rami S.
    CANCER, 2015, 121 (06) : 876 - 882
  • [26] A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
    Ross, David M.
    Arbelaez, Alejandro
    Chee, Lynette C. Y.
    Fong, Chun Yew
    Hiwase, Devendra
    Kannourakis, George
    Kwan, John
    Liang, James
    Puliyayi, Anish
    Rose, Hannah
    Tan, Shuhying
    Teh, Tse-Chieh
    esterman, David Alan
    Wight, Joel
    Rovaldi, Chris
    Furutani, Elissa M.
    Gaggi, Adrienne
    Jiang, Ying
    Lachey, Jenn
    Natarajan, Harveen Dhillon
    Ordonez, Claudia
    BLOOD, 2021, 138 : 3675 - +
  • [27] Results of a Randomized, Double-Blind Study of Romiplostim Versus Placebo in Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome and Thrombocytopenia
    Giagounidis, Aristoteles
    Mufti, Ghulam J.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Szer, Jeffrey
    Platzbecker, Uwe
    Kuendgen, Andrea
    Gaidano, Gianluca
    Wiktor-Jedrzejczak, Wieslaw
    Hu, Kuolung
    Woodard, Paul
    Yang, Allen S.
    Kantarjian, Hagop M.
    CANCER, 2014, 120 (12) : 1838 - 1846
  • [28] Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors.
    Tolcher, Anthony W.
    Victoria, Ivan
    Germann, Nathalie
    Luecke, Stephan
    Bailey, Mark
    Kordes, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] An open-label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate
    Fearon, KCH
    Falconer, JS
    Ross, JA
    Carter, DC
    Hunter, JO
    Reynolds, PD
    Tuffnell, Q
    ANTICANCER RESEARCH, 1996, 16 (02) : 867 - 874
  • [30] TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)
    Colombo, Ilaria
    Koster, Kira-Lee
    Holer, Lisa
    Haefliger, Simon
    Rabaglio, Manuela
    Bastian, Sara
    Schwitter, Michael
    Eckhardt, Katrin
    Hayoz, Stefanie
    McLaughlin, Anna M.
    Kloft, Charlotte
    Klose, Marian
    Halbherr, Stefan
    Baumgartner, Christian
    Sessa, Cristiana
    Stathis, Anastasios
    Hess, Dagmar
    Joerger, Markus
    EUROPEAN JOURNAL OF CANCER, 2024, 201
12345